Drugs under early investigation for the treatment of bipolar disorder

Bibliography

• National Institute for Health and Care Excellence (NICE). Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. NICE clinical guideline 185. September 2014
   Google Scholar
• Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 2005;67(1):1–8
   PubMed Web of Science ®Google Scholar
• Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014;1(5):351–9
   PubMed Web of Science ®Google Scholar
• Bauer M, Glenn T, Alda M, et al. Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data. Int J Bipolar Disord 2013;1:5
   PubMedGoogle Scholar
• Weinstock LM, Gaudiano BA, Epstein-Lubow G, et al. Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res 2014;216:24–30
   PubMed Web of Science ®Google Scholar
• Judd JL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530–7
   PubMed Web of Science ®Google Scholar
• Judd JL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261–9
   PubMed Web of Science ®Google Scholar
• MacQueen GM, Young LT, Joffe RT. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 2001;103:163–70
   PubMed Web of Science ®Google Scholar
• Burdick KE, Braga RJ, Goldberg JF, et al. Cognitive dysfunction in bipolar disorder. CNS Drugs 2007;21(12):971–81
   PubMed Web of Science ®Google Scholar
• Angst J, Azorin J-M, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry 2011;68(8):791–9
   PubMed Web of Science ®Google Scholar
• Hoertel N, Strat YL, Angst J, et al. Subthreshold bipolar disorder in a U.S. national representative sample: prevalence, correlates and perspectives for psychiatric nosography. J Affect Disord 2013;146(3):338–47
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: www.clinicaltrials.gov [Last assessed 10 November 2014]
   Google Scholar
• European Union Clinical Trials Register. Available from: www.clinicaltrialsregister.eu/ctr-search/search [Last assessed 10 November 2014]
   Google Scholar
• International Clinical Trials Registry Platform. Available from: www. apps.who.int/trialsearch/Default.aspx [Last assessed 10 November 2014]
   Google Scholar
• Center Watch. Available from: www.centerwatch.com/clinical-trials/listings [Last assessed 10 November 2014]
   Google Scholar
• Verrotti A, Loiacono G, Rossi A, et al. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy. Epilepsy Res 2014;108(1):1–10
   PubMed Web of Science ®Google Scholar
• Nunes T, Almeida L, Costa R, et al. Efficacy, safety and tolerability of eslicarbazepine acetate in the recurrence prevention of bipolar I disorder: BIA-2093-205 phase II extension study. J Neurol Sci 2013;333(1):42
   Google Scholar
• Keck PEJr, Hsu HA, Papadakis K, et al. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 2009;32(4):199–204
   PubMed Web of Science ®Google Scholar
• Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2012;14(1):64–70
   PubMed Web of Science ®Google Scholar
• Koukopoulos A, Serra G, Koukopoulos AE, et al. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord 2012;136(1-2):163–6
   PubMed Web of Science ®Google Scholar
• Lee SY, Chen SL, Chang YH, et al. Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. J Psychiatr Res 2013;47(10):1343–8
   PubMed Web of Science ®Google Scholar
• Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012;73(1):81–6
   PubMed Web of Science ®Google Scholar
• Carlezon WA, Pliakas AM, Parow AM, et al. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry 2002;51(11):882–9
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Lyoo IK, Haws C, et al. Decreased glutamate/glutamine levels may mediate cytidine’s efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2009;34(7):1810–18
   PubMed Web of Science ®Google Scholar
• Murphy BL, Stoll AL, Harris PQ, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol 2012;32(5):699–703
   PubMed Web of Science ®Google Scholar
• Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56(5):407–12
   PubMed Web of Science ®Google Scholar
• Schaffer LC, Schaffer CB, Miller AR, et al. An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. J Affect Disord 2013;147:407–10
   PubMed Web of Science ®Google Scholar
• Toyoda A, Iio W. Antidepressant-like effect of chronic taurine administration and its hippocampal signal transduction in rats. Adv Exp Med Biol 2013;775:29–43
   PubMed Web of Science ®Google Scholar
• Oja SS, Saransaari P. Taurine and epilepsy. Epilepsy Res 2013;104(3):187–94
   PubMed Web of Science ®Google Scholar
• Goldstein I, Levy T, Galili D, et al. Involvement of Na(+), K(+)-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry 2006;60(5):491–9
   PubMed Web of Science ®Google Scholar
• Mukai T, Kishi T, Matsuda Y, et al. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014;29(1):55–63
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Levine J, Gershon S, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000;2(1):47–55
   PubMed Web of Science ®Google Scholar
• Eden Evins A, Demopulos C, Yovel I, et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006;8(2):168–74
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011;77(13):1253–62
   PubMed Web of Science ®Google Scholar
• Grunze H, Almeida L, Nunes T, et al. Efficacy and safety of eslicarbazepine acetate in acute manic episodes associated with bipolar I disorder: BIA-2093-203 phase II study results. J Neurol Sci 2013;333(1):42
   Google Scholar
• Cohen BM, Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol 2008;11(2):243–7
   PubMed Web of Science ®Google Scholar
• Effects of pentazocine on manic symptoms. Available from: www. clinicaltrials.gov/ct2/show/results/NCT00125931 [Last Accessed 10 November 2014]
   Google Scholar
• Effects of Pentazocine versus lorazepam or placebo on manic symptoms. Available from: www. clinicaltrials.gov/ct2/show/results/NCT00431184?term=pentazocine&rank=1 [Last accessed 10 November 2014]
   Google Scholar
• Ghanizadeh A, Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress Anxiety 2013;30(11):1084–8
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Omrani Sigaroodi M, et al. Lovastatin as an adjuvant to lithium for treating manic phase of bipolar disorder: a 4-week, randomized, double-blind, placebo-controlled clinical trial. Depress Res Treat 2014;2014:730505
   PubMedGoogle Scholar
• Gao Y, Payne RS, Schurr A, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res 2011;188(3):366–71
   PubMed Web of Science ®Google Scholar
• Faridhosseini F, Sadeghi R, Farid L, et al. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014;29(3):216–23
   PubMed Web of Science ®Google Scholar
• Efficacy of celecoxib as an adjunct in the treatment of bipolar disorder: A double blind and placebo controlled trial. Available from: www. irct.ir/searchresult.php?keyword=fibrinogen&id=1556&field=&number=53&prt=69&total=5&m=1 [Last accessed 10 November 2014]
   Google Scholar
• Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther 2013;30(2):102–13
   PubMed Web of Science ®Google Scholar
• Forest Laboratories, Inc. and Gedeon Richter Plc. Forest Laboratories, Inc. and Gedeon Richter Plc. Announce positive phase IIb topline results for cariprazine for the treatment of bipolar depression. Available from: www. news.frx.com/press-release/r-and-d-news/forest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase–0 [Last accessed 10 November 2014]
   Google Scholar
• Zarate CAJr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57:430–2
   PubMed Web of Science ®Google Scholar
• Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010;35(3):834–46
   PubMed Web of Science ®Google Scholar
• Chakrabarti S. Thyroid functions and bipolar affective disorder. J Thyroid Res 2011;2011:306367
   PubMedGoogle Scholar
• Stamm TJ, Lewitzka U, Sauer C, et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;75(2):162–8
   PubMed Web of Science ®Google Scholar
• Brennan BP, Jensen JE, Hudson JI, et al. A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol 2013;33(5):627–35
   PubMed Web of Science ®Google Scholar
• Fornaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat 2013;9:243–51
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder – a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64(6):468–75
   PubMed Web of Science ®Google Scholar
• Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011;135:389–94
   PubMed Web of Science ®Google Scholar
• Repligen Corp. Repligen announces plans to initiate a phase 2b trial for RG2417 in bipolar disorder. Available from: www.medicalnewstoday.com/articles/111085.php [Last accessed at 10 November 2014]
   Google Scholar
• Asenapine for bipolar depression. Available from: www. clinicaltrials.gov/ct2/show/NCT01807741?term=NCT01807741&rank=1 [Last accessed 10 November 2014]
   Google Scholar
• Ostacher MJ, Iosifescu DV, Hay A, et al. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. Bipolar Disord 2014;16(2):199–203
   PubMed Web of Science ®Google Scholar
• Rahola JG. Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? Curr Neuropharmacol 2012;10(2):139–58
   PubMed Web of Science ®Google Scholar
• While A, Keen L. The effects of statins on mood: a review of the literature. Eur J Cardiovasc Nurs 2012;11(1):85–96
   PubMed Web of Science ®Google Scholar
• Desbonnet L, Garrett L, Clarke G, et al. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 2010;170(4):1179–88
   PubMed Web of Science ®Google Scholar
• Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses 2005;64(3):533–8
   PubMed Web of Science ®Google Scholar
• Miskowiak KW, Vinberg M, Harmer CJ, et al. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials 2010;11:97
   PubMed Web of Science ®Google Scholar
• Miskowiak KW, Ehrenreich H, Christensen EM, et al. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry 2014;75(12):1347–55
   PubMed Web of Science ®Google Scholar
• Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29(8):1538–45
   PubMed Web of Science ®Google Scholar
• Watson S, Gallagher P, Porter RJ, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry 2012;72(11):943–9
   PubMed Web of Science ®Google Scholar
• Kluge M, Hegerl U, Sander C, et al. Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. BMC Psychiatry 2013;13:71
   PubMed Web of Science ®Google Scholar
• Dell’Osso B, Ketter TA. Use of adjunctive stimulants in adult bipolar depression. Int J Neuropsychopharmacol 2013;16(1):55–68
   PubMed Web of Science ®Google Scholar
• Li D, Herrera S, Bubula N, et al. Casein kinase 1 enables nucleus accumbens amphetamine-induced locomotion by regulating AMPA receptor phosphorylation. J Neurochem 2011;118:237–47
   PubMed Web of Science ®Google Scholar
• Arey R, McClung CA. An inhibitor of casein kinase 1 ϵ/δ partially normalizes the manic-like behaviors of the ClockΔ19 mouse. Behav Pharmacol 2012;23(4):392–6
   PubMed Web of Science ®Google Scholar
• Posser T, Kaster MP, Baraúna SC, et al. Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. Eur J Pharmacol 2009;602(1):85–91
   PubMed Web of Science ®Google Scholar
• Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nat Commun 2013;4:1332
   PubMed Web of Science ®Google Scholar
• Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004;65(1):10–21
   PubMed Web of Science ®Google Scholar
• Gould TD, Einat H, Bhat R, et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004;7:387–90
   PubMed Web of Science ®Google Scholar
• O’Brien WT, Harper AD, Jové F, et al. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004;24:6791–8
   PubMed Web of Science ®Google Scholar
• Du J, Wei Y, Liu L, et al. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci USA 2010;107(25):11573–8
   PubMed Web of Science ®Google Scholar
• Chen W, Gaisina I, Gunosewoyo H, et al. Structure-guided design of a highly selective glycogen synthase kinase-3β inhibitor: a superior neuroprotective pyrazolone showing antimania effects. ChemMedChem 2011;6(9):1587–92
   PubMed Web of Science ®Google Scholar
• Kalinichev M, Dawson LA. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol 2011;14(8):1051–67
   PubMed Web of Science ®Google Scholar
• Schroeder FA, Lewis MC, Fass DM, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS One 2013;8(8):e71323
   PubMed Web of Science ®Google Scholar
• Steckert AV, Valvassori SS, Varela RB, et al. Effects of sodium butyrate on oxidative stress and behavioral changes induced by administration of D-AMPH. Neurochem Int 2013;62(4):425–32
   PubMed Web of Science ®Google Scholar
• Stertz L, Fries GR, Aguiar BW, et al. Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania. Rev Bras Psiquiatr 2014;36(1):39–46
   PubMed Web of Science ®Google Scholar
• Moretti M, Valvassori SS, Varela RB, et al. Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behav Pharmacol 2011;22(8):766–72
   PubMed Web of Science ®Google Scholar
• Resende WR, Valvassori SS, Réus GZ, et al. Effects of sodium butyrate in animal models of mania and depression: implications as a new mood stabilizer. Behav Pharmacol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Valvassori SS, Varela RB, Arent CO, et al. Sodium butyrate functions as an antidepressant and improves cognition with enhanced neurotrophic expression in models of maternal deprivation and chronic mild stress. Curr Neurovasc Res 2014;11(4):359–66
   PubMed Web of Science ®Google Scholar
• Dencker D, Dias R, Pedersen ML, et al. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav 2008;12:49–53
   PubMed Web of Science ®Google Scholar
• Kristensen LV, Sandager-Nielsen K, Hansen HH. K(v) 7 (KCNQ) channel openers normalize central 2-deoxyglucose uptake in a mouse model of mania and increase prefrontal cortical and hippocampal serine-9 phosphorylation levels of GSK3β. J Neurochem 2012;121(3):373–82
   PubMed Web of Science ®Google Scholar
• Etain B, Lajnef M, Bellivier F, et al. Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States. J Clin Psychiatry 2012;73(4):e561–6
   PubMedGoogle Scholar
• Samalin L, Llorca PM, Giordana B, et al. Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYMUM study). J Affect Dis 2014;159:94–102
   PubMed Web of Science ®Google Scholar
• Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14(8):1029–49
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97
   PubMed Web of Science ®Google Scholar
• Alsaif M, Haenisch F, Guest PC, et al. Challenges in drug target discovery in bipolar disorder. Expert Opin Ther Targets 2013;17(5):565–77
   PubMed Web of Science ®Google Scholar
• Hoertel N, de Maricourt P, Gorwood P. Novel routes to bipolar disorder drug discovery. Expert Opin Drug Discov 2013;8(8):907–18
   PubMed Web of Science ®Google Scholar
• Lu RB, Chen SL, Lee SY, et al. Neuroprotective and neurogenesis agent for treating bipolar II disorder: add-on memantine to mood stabilizer works. Med Hypotheses 2012;79(2):280–3
   PubMed Web of Science ®Google Scholar
• Balanzá-Martínez V, Fries GR, Colpo GD, et al. Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Rev Neurother 2011;11(7):1029–47
   PubMed Web of Science ®Google Scholar
• Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 2010;35:2143–54
   PubMed Web of Science ®Google Scholar
• Norris ER, Karen Burke Correll JR, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 2013;144(1-2):141–7
   PubMed Web of Science ®Google Scholar
• Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2014;17(1):63–75
   PubMed Web of Science ®Google Scholar
• Sanches M, Bauer IE, Galvez JF, et al. The management of cognitive impairment in bipolar disorder: current status and perspectives. Am J Ther 2014; Epub ahead of print
   PubMedGoogle Scholar
• Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci 2010;13(10):1161–9
   PubMed Web of Science ®Google Scholar
• Bouaziz M, Ambroise C, Guedj M. Accounting for population stratification in practice: a comparison of the main strategies dedicated to genome-wide association studies. PLoS One 2011;6(12):e28845
   PubMed Web of Science ®Google Scholar
• Soreca I, Fagiolini A, Frank E, et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 2008;42(11):956–61
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Lavaud P, et al. Generalizability of clinical trial results for bipolar disorder to community samples. J Clin Psychiatry 2013;74(3):265–70
   PubMed Web of Science ®Google Scholar